✦ LIBER ✦

Improving survival in myelodysplastic syndromes

✍ Scribed by Guillermo Garcia-Manero

Book ID: 117784959
Publisher: The Lancet
Year: 2009
Tongue: English
Weight: 189 KB
Volume: 10
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(09)70048-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prolonged survival with improved tolerab

Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C

✍ Pierre Fenaux; Norbert Gattermann; John F. Seymour; Eva Hellström-Lindberg; Ghul 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB

Effect of haematological improvement on

Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome

✍ Masamitsu Yanada; Xuelin Huang; Guillermo Garcia-Manero; Susan O'Brien; Farhad R 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

Transplantation in Remission Improves th

Transplantation in Remission Improves the Disease-Free Survival of Patients with Advanced Myelodysplastic Syndromes Treated with Myeloablative T Cell-Depleted Stem Cell Transplants from HLA-Identical Siblings

✍ Hugo Castro-Malaspina; Ann A. Jabubowski; Esperanza B. Papadopoulos; Farid Boula 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 290 KB

Is survival enough for myelodysplastic s

Is survival enough for myelodysplastic syndromes?

✍ Valeria Santini 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 92 KB

Validation of survival-predictive models

Validation of survival-predictive models in myelodysplastic syndromes

✍ Miguel A. Sanz; J. Ignacio Lorenzo; Guillermo F. Sanz; Sonia Garcia; Victoria Am 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

Myelodysplastic syndromes : Incidence an

Myelodysplastic syndromes : Incidence and survival in the United States

✍ Xiaomei Ma; Monique Does; Azra Raza; Susan T. Mayne 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB 👁 1 views

## Abstract ## BACKGROUND. Myelodysplastic syndromes (MDS) became reportable to the Surveillance, Epidemiology, and End Results (SEER) Program (the United States cancer surveillance program) in 2001. This provided the first opportunity to examine the incidence and survival of patients with MDS in